11741 Results

People

  1. Vickers
    Vickers
  2. Offit
    Offit
  3. Robson
    Robson
  4. Horwitz
    Horwitz
  5. Kingham
    Kingham
  6. Panageas
    Panageas
  7. Breitbart
    Breitbart
  8. Halpern
    Halpern
  9. Jarnagin
    Jarnagin
  10. Nelson
    Nelson

Groups

  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)
  7. Psychiatry and Behavioral Sciences, Department of (2780)
  8. Biostatistics Service (2339)
  9. GSK Faculty (2009)
  10. Health Outcomes Research Group (1948)
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (7144)
  2. Meeting Abstract (3307)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (236)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11741)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: The largest multicenter retrospective analysis
    Meeting Abstract

    Mehta-Shah, N.; Kommalapati, A.; Teja, S.; Cashen, A. F.; Dahi, P. B.; Sauter, C. S.; Moskowitz, A. J.; Jacobsen, E. D.; William, B. M.; Ozga, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • End of treatment peripheral blood T-cell receptor gene rearrangement evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Fehniger, T. A.; Jacobsen, E. D.; Peterson, K.; Kahl, B. S.; Bartlett, N. L.; Cashen, A. F.; Ghobadi, A.; Fischer, A.; Reagan, B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma
    Meeting Abstract

    Khodadoust, M. S.; Feldman, T. A.; Yoon, D. H.; Yannakou, C. K.; Radeski, D.; Kim, Y. H.; Mehta-Shah, N.; Khot, A.; Wilcox, R. A.; Kim, W. S.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Trial-in-progress: Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma with less than 10% CD30 expression
    Meeting Abstract

    Jagadeesh, D.; Sims, R. B.; Horwitz, S. M.
    Blood (2020)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies
    Meeting Abstract

    Horwitz, S. M.; Foran, J. M.; Maris, M.; Sawas, A.; Okada, C.; Feldman, T. A.; Minden, M. D.; Sokol, L.; Mei, M.; Flinn, I. W.; more...
    Blood (2020)

    Fulltext@MSK | Save